Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Clinical & Translational Metabolism
Erschienen in: Clinical & Translational Metabolism 1/2024

01.12.2024 | Review

Natural Products and Traditional Herbal Medicines as Managerial Therapies to Combat Rheumatoid Arthritis

verfasst von: Neha Ghosh, Shivam Pathak, Malsawmdawngkimi, Gautam Kumar, Azka Gull

Erschienen in: Clinical & Translational Metabolism | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Rheumatoid arthritis (RA) is a complex and challenging autoimmune disease characterized by chronic inflammation of the joints, discomfort, stiffness, functional impairment, and systemic complications that affect millions of people around the world. Despite advances in medication, controlling RA remains difficult due to its complicated pathophysiology and numerous clinical symptoms. Synthetic medications, while effective, frequently cause considerable adverse effects, necessitating the investigation of alternate therapeutic options. This study attempts to provide a complete overview of synthetic medications and natural items used to treat RA. It specifically investigates the pathophysiological mechanisms that underpin RA and the efficacy and safety profiles of synthetic pharmaceuticals. Synthetic medications, such as disease-modifying antirheumatic drugs (DMARDs), and biologics remain important treatments for RA, albeit with hazards. So to explore safer and more effective therapy for the treatment of RA, a need to exploit the possible therapeutic benefits of natural items such as antioxidants, plant secondary metabolites, and traditional herbal remedies arises. By encompassing a spectrum of insights, from the molecular level to holistic traditional practices, this review aims to provide a holistic understanding of the role of natural products and traditional herbal medicines in the managerial landscape of RA. Furthermore, it investigates the effect of nutrition in regulating inflammation and disease development in RA. Integrative techniques that use natural products present intriguing adjuvant therapy, delivering anti-inflammatory, analgesic, and immunomodulatory effects with potentially fewer side effects. Understanding the interaction of synthetic medications and natural products, as well as the role of nutrition, can help enhance RA treatment regimens, improve patient outcomes, and reduce treatment-related problems. This study is a valuable resource for doctors, researchers, and patients looking for evidence-based methods for RA care. The synthesis of this knowledge contributes to the ongoing pursuit of enhanced therapeutic strategies, fostering improved outcomes and quality of life for individuals grappling with rheumatoid arthritis.
Literatur
1.
Debreova M, Culenova M, Smolinska V, Nicodemou A, Csobonyeiova M, Danisovic L. Rheumatoid arthritis: from synovium biology to cell-based therapy. Cytotherapy. 2022;24(4):365–75.PubMedCrossRef
2.
3.
Gupta BM, Gupta R, Kumar A, Bansal M. Rheumatoid arthritis research in India: a scientometric assessment of publications during 2007–2016.  SF J Orthopedic Rheumatol 2018.
4.
5.
McGraw WT, Potempa J, Farley D, Travis J. Purification, characterization, and sequence analysis of a potential virulence factor from Porphyromonas gingivalis, peptidylarginine deiminase. Infect Immun. 1999;67(7):3248–56.PubMedPubMedCentralCrossRef
6.
7.
Anderson AS, Loeser RF. Why is osteoarthritis an age-related disease?, Best practice & research. Clin Rheumatol. 2010;24(1):15–26.
8.
Littlejohn EA, Monrad SU. Early diagnosis and treatment of rheumatoid arthritis. Primary care: Clinics in office practice. 2018;45(2):237–55.PubMedCrossRef
9.
Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone res. 2018;6(1):15.PubMedPubMedCentralCrossRef
10.
Cojocaru M, Cohocaru IM, Chico B. New insight into the rheumatoid vasculitis. Rom J Intern Med. 2015;53(2):128–32.PubMed
11.
12.
Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320(13):1360–72.PubMedCrossRef
13.
Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. The Lancet. 2017;389(10086):2338–48.CrossRef
14.
Watanabe R, Okano T, Gon T, Yoshida N, Fukumoto K, Yamada S, Hashimoto M. Difficult-to-treat rheumatoid arthritis: current concept and unsolved problems. Front Med (Lausanne). 2022;9:1049875.PubMedCrossRef
15.
Wang Y, Chen S, Du K, Liang C, Wang S, Boadi EO, Li J, Pang X, He J. Chang Y-x, Traditional herbal medicine: therapeutic potential in rheumatoid arthritis. J Ethnopharmacol. 2021;279: 114368.PubMedCrossRef
16.
Joensuu JT, Aaltonen KJ, Aronen P, Sokka T, Puolakka K, Tuompo R, Korpela M, Vasala M, Ilva K, Nordström D. Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a register study. Rheumatology. 2016;55(10):1803–11.PubMedCrossRef
17.
Papadopoulou D, Roumelioti F, Tzaferis C, Chouvardas P, Pedersen A-K, Charalampous F, Christodoulou-Vafeiadou E, Ntari L, Karagianni N, Denis MC. Repurposing the antipsychotic drug amisulpride for targeting synovial fibroblast activation in arthritis. JCI insight. 2023;8:9.CrossRef
18.
Benjamin O, Goyal A, Lappin SL. Disease-modifying antirheumatic drugs (DMARD). In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.
19.
Choi J, Fenando A. Sulfasalazine. StatPearls, StatPearls Publishing; 2022.
20.
Ghlichloo I, Gerriets V. Nonsteroidal anti-inflammatory drugs (NSAIDs). StatPearls, StatPearls Publishing; 2023.
21.
Waller DG, Sampson AP. 30 - Rheumatoid arthritis, other inflammatory arthritides and osteoarthritis, in: D.G. Waller, A.P. Sampson (Eds.). Medical Pharmacology and Therapeutics (Fifth Edition). Elsevier; 2018. pp. 373–383.
22.
Cohen S, Tuckwell K, Katsumoto TR, Zhao R, Galanter J, Lee C, Rae J, Toth B, Ramamoorthi N, Hackney JA. Fenebrutinib versus placebo or adalimumab in rheumatoid arthritis: a randomized, double-blind, phase II trial. Arthritis Rheumatol. 2020;72(9):1435–46.PubMedPubMedCentralCrossRef
23.
Wu H, Yan S, Chen J, Luo X, Li P, Jia X, Dai X, Wang C, Huang Q, Liu L. JAK1-STAT3 blockade by JAK inhibitor SHR0302 attenuates inflammatory responses of adjuvant-induced arthritis rats and decreases Th17 and total B cells. Joint Bone Spine. 2016;83(5):525–32.PubMedCrossRef
24.
Conaghan PG, Nowak M, Du S, Luo Y, Landis J, Pachai C, Fura A, Catlett IM, Grasela DM, Østergaard M. Evaluation of BMS-986142, a reversible Bruton’s tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design study. Lancet Rheumatol. 2023;5(5):e263–73.PubMedCrossRef
25.
Tanaka Y, Genovese MC, Matsushima H, Long-term safety, efficacy, and patient-centered outcomes of filgotinib in the treatment of rheumatoid arthritis: current perspectives, patient preference and adherence 2023;2499–2516.
26.
Peterfy CG, Strand V, Friedman A, Hall S, Mysler E, Durez P, Baraliakos X, Enejosa JV, Shaw T, Li Y. Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program. Rheumatology. 2022;61(8):3246–56.PubMedCrossRef
27.
Daien C, Krogulec M, Gineste P, Steens J-M, Du Roure LD, Biguenet S, Scherrer D, Santo J, Ehrlich H, Durez P. Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study. Ann Rheum Dis. 2022;81(8):1076–84.PubMedCrossRef
28.
Yoon S-B, Hong H, Lim H-J, Choi JH, Choi YP, Seo SW, Lee HW, Chae CH, Park W-K, Kim HY. A novel IRAK4/PIM1 inhibitor ameliorates rheumatoid arthritis and lymphoid malignancy by blocking the TLR/MYD88-mediated NF-κB pathway. Acta Pharmaceutica Sinica B. 2023;13(3):1093–109.PubMedCrossRef
29.
Li J, Li M, Wu D, Zhou J. Leung S-o, Zhang F, SM03, an anti-human CD22 monoclonal antibody, for active rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled study. Rheumatology. 2022;61(5):1841–8.PubMedCrossRef
30.
Gordon D, Kivitz A, Singhal A, Burt D, Bangs MC, Huff EE, Hope HR, Monahan JB. Selective inhibition of the MK2 pathway: data from a phase IIa randomized clinical trial in rheumatoid arthritis. ACR Open Rheumatology. 2023;5(2):63–70.PubMedPubMedCentralCrossRef
31.
Robak E, Robak T. Bruton’s kinase inhibitors for the treatment of immunological diseases: current status and perspectives. J Clin Med. 2022;11(10):2807.PubMedPubMedCentralCrossRef
32.
Montalban X, Wallace D, Genovese MC, et al. Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis. J Neurol Neurosurg Psychiatry. 2023;94(1):1–9.PubMedCrossRef
33.
Abuelazm M, Ghanem A, Mahmoud A, et al. The efficacy and safety of olokizumab for rheumatoid arthritis: a systematic review, pairwise, and network meta-analysis. Clin Rheumatol. 2023;42(6):1503–20.PubMedPubMedCentralCrossRef
34.
Takeuchi T, Chino Y, Kawanishi M, Nakanishi M, Watase H, Mano Y, Sato Y, Uchida S, Tanaka Y. Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials. Arthritis Res Ther. 2023;25(1):60.PubMedPubMedCentralCrossRef
35.
Taylor PC, Weinblatt ME, McInnes IB, Atsumi T, Strand V, Takeuchi T, Bracher M, Brooks D, Davies J, Goode C. Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3). Ann Rheum Dis. 2023;82(12):1527–37.PubMedCrossRef
36.
Muralidharan S, Njenga M, Garron T, Bondensgaard K, Paolini JF. Preclinical immunopharmacologic assessment of KPL-404, a novel, humanized, non-depleting antagonistic anti-CD40 monoclonal antibody. J Pharmacol Exp Ther. 2022;381(1):12–21.PubMedCrossRef
37.
Buttgereit F, Aelion J, Rojkovich B, Zubrzycka-Sienkiewicz A, Chen S, Yang Y, Arikan D, D’Cunha R, Pang Y, Kupper H. Efficacy and safety of ABBV-3373, a novel anti–tumor necrosis factor glucocorticoid receptor modulator antibody–drug conjugate, in adults with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a randomized, double-blind, active-controlled proof-of-concept phase IIa trial. Arthritis & Rheumatology. 2023;75(6):879–89.CrossRef
38.
Deligiannidou G-E, Gougoula V, Bezirtzoglou E, Kontogiorgis C, Constantinides TK. The role of natural products in rheumatoid arthritis: current knowledge of basic in vitro and in vivo research. Antioxidants. 2021;10(4):599.PubMedPubMedCentralCrossRef
39.
Edilova MI, Akram A, Abdul-Sater AA. Innate immunity drives pathogenesis of rheumatoid arthritis. biomed j. 2021;44(2):172–82.PubMedCrossRef
40.
Laurindo LF, de Maio MC, Barbalho SM, Guiguer EL, Araújo AC, de Alvares GR, Flato UAP, Júnior EB, Detregiachi CRP, dos Santos Haber JF. Organokines in rheumatoid arthritis: a critical review. Int J Mol Sci. 2022;23(11):6193.PubMedPubMedCentralCrossRef
41.
Veselinovic M, Barudzic N, Vuletic M, Zivkovic V, Tomic-Lucic A, Djuric D, Jakovljevic V. Oxidative stress in rheumatoid arthritis patients: relationship to diseases activity. Mol Cell Biochem. 2014;391:225–32.PubMedCrossRef
42.
Wang X, Fan D, Cao X, Ye Q, Wang Q, Zhang M, Xiao C. The role of reactive oxygen species in the rheumatoid arthritis-associated synovial microenvironment. Antioxidants. 2022;11(6):1153.PubMedPubMedCentralCrossRef
43.
Finaud J, Lac G, Filaire E. Oxidative stress: relationship with exercise and training. Sports Med. 2006;36:327–58.PubMedCrossRef
44.
45.
Mititelu RR, Pădureanu R, Băcănoiu M, Pădureanu V, Docea AO, Calina D, Barbulescu AL, Buga AM. Inflammatory and oxidative stress markers—mirror tools in rheumatoid arthritis. Biomedicines. 2020;8(5):125.PubMedPubMedCentralCrossRef
46.
Hitchon CA, El-Gabalawy HS. Oxidation in rheumatoid arthritis. Arthritis Res Ther. 2004;6(6):1–14.CrossRef
47.
Cerhan JR, Saag KG, Merlino LA, Mikuls TR, Criswell LA. Antioxidant micronutrients and risk of rheumatoid arthritis in a cohort of older women. Am J Epidemiol. 2003;157(4):345–54.PubMedCrossRef
48.
49.
50.
Traber MG. Atkinson J. Vitamin E, antioxidant and nothing more, free radical biology and medicine. 2007;43(1):4–15.PubMed
51.
Kamanlı A, Nazıroğlu M, Aydılek N, Hacıevlıyagil C. Plasma lipid peroxidation and antioxidant levels in patients with rheumatoid arthritis. Cell Biochem Funct. 2004;22(1):53–7.PubMedCrossRef
52.
Elmadfa R. Majchrzak. Wagner, Genser, Lettner, Pinter, Effects of beta-carotene supplementation on free radical mechanism in healthy adult subjects, International journal for vitamin and nutrition research. 2004;74(2):147–52.PubMed
53.
54.
Turrubiates-Hernández FJ, Márquez-Sandoval YF, González-Estevez G, Reyes-Castillo Z, Muñoz-Valle JF. The relevance of selenium status in rheumatoid arthritis. Nutrients. 2020;12(10):3007.PubMedPubMedCentralCrossRef
55.
56.
Shankar AH, Prasad AS. Zinc and immune function: the biological basis of altered resistance to infection. Am J Clin Nutr. 1998;68(2):447S-463S.PubMedCrossRef
57.
Calder PC. Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance. Biochim Biophys Acta Mol Cell Biol Lipids. 2015;1851(4):469–84.CrossRef
58.
Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA. 2012;308(10):1024–33.PubMedCrossRef
59.
Qi W, Lin C, Fan K, Chen Z, Liu L, Feng X, Zhang H, Shao Y, Fang H, Zhao C, Zhang R, Cai D. Hesperidin inhibits synovial cell inflammation and macrophage polarization through suppression of the PI3K/AKT pathway in complete Freund’s adjuvant-induced arthritis in mice. Chem Biol Interact. 2019;306:19–28.PubMedCrossRef
60.
Zhai K-F, Duan H, Cui C-Y, Cao Y-Y, Si J-L, Yang H-J, Wang Y-C, Cao W-G, Gao G-Z, Wei Z-J. Liquiritin from Glycyrrhiza uralensis attenuating rheumatoid arthritis via reducing inflammation, suppressing angiogenesis, and inhibiting MAPK signaling pathway. J Agric Food Chem. 2019;67(10):2856–64.PubMedCrossRef
61.
Li X, Xie P, Hou Y, Chen S, He P, Xiao Z, Zhan J, Luo D, Gu M, Lin D. Tangeretin inhibits oxidative stress and inflammation via upregulating Nrf-2 signaling pathway in collagen-induced arthritic rats. Pharmacology. 2019;104(3–4):187–95.PubMedCrossRef
62.
Cheng W-X, Huang H, Chen J-H, Zhang T-T, Zhu G-Y, Zheng Z-T, Lin J-T, Hu Y-P, Zhang Y, Bai X-L, Wang Y, Xu Z-W, Song B, Mao Y-Y, Yang F, Zhang P. Genistein inhibits angiogenesis developed during rheumatoid arthritis through the IL-6/JAK2/STAT3/VEGF signalling pathway. J Orthop Transl. 2020;22:92–100.
63.
Liu X, Wang Z, Qian H, Tao W, Zhang Y, Hu C, Mao W, Guo Q. Natural medicines of targeted rheumatoid arthritis and its action mechanism. Front Immunol. 2022;13: 945129.PubMedPubMedCentralCrossRef
64.
Yuan K, Zhu Q, Lu Q, Jiang H, Zhu M, Li X, Huang G, Xu A. Quercetin alleviates rheumatoid arthritis by inhibiting neutrophil inflammatory activities. J Nutr Biochem. 2020;84: 108454.PubMedCrossRef
65.
Feng Z-T, Yang T, Hou X-Q, Wu H-Y, Feng J-T, Ou B-J, Cai S-J, Li J, Mei Z-G. Sinomenine mitigates collagen-induced arthritis mice by inhibiting angiogenesis. Biomed Pharmacother. 2019;113.PubMedCrossRef
66.
Liang J, Chang B, Huang M, Huang W, Ma W, Liu Y, Tai W, Long Y, Lu Y. Oxymatrine prevents synovial inflammation and migration via blocking NF-κB activation in rheumatoid fibroblast-like synoviocytes. Int Immunopharmacol. 2018;55:105–11.PubMedCrossRef
67.
Xu R, Liu Z, Hou J, Huang T, Yang M. Osthole improves collagen-induced arthritis in a rat model through inhibiting inflammation and cellular stress. Cell Mol Biol Lett. 2018;23(1):1–11.CrossRef
68.
Lin W, Chen G, Mao Y, Ma X, Zhou J, Yu X, Wang C, Liu M. Imperatorin inhibits proliferation, migration, and inflammation via blocking the NF-κB and MAPK pathways in rheumatoid fibroblast-like synoviocytes. ACS Omega. 2022;7(34):29868–76.PubMedPubMedCentralCrossRef
69.
Wang W, Sun W, Jin L. Caffeic acid alleviates inflammatory response in rheumatoid arthritis fibroblast-like synoviocytes by inhibiting phosphorylation of IκB kinase α/β and IκBα. Int Immunopharmacol. 2017;48:61–6.PubMedCrossRef
70.
Fikry EM, Gad AM, Eid AH, Arab HH. Caffeic acid and ellagic acid ameliorate adjuvant-induced arthritis in rats via targeting inflammatory signals, chitinase-3-like protein-1 and angiogenesis. Biomed Pharmacother. 2019;110:878–86.PubMedCrossRef
71.
Liu N, Feng X, Wang W, Zhao X, Li X. Paeonol protects against TNF-α-induced proliferation and cytokine release of rheumatoid arthritis fibroblast-like synoviocytes by upregulating FOXO3 through inhibition of miR-155 expression. Inflamm Res. 2017;66(7):603–10.PubMedCrossRef
72.
Meng D, Li J, Li H, Wang K. Salvianolic acid B remits LPS-induced injury by up-regulating miR-142-3p in MH7A cells. Biomed Pharmacother. 2019;115: 108876.PubMedCrossRef
73.
Mohammadian Haftcheshmeh S, Khosrojerdi A, Aliabadi A, Lotfi S, Mohammadi A, Momtazi-Borojeni AA. Immunomodulatory effects of curcumin in rheumatoid arthritis: evidence from molecular mechanisms to clinical outcomes. Rev Physiol Biochem Pharmacol. 2021;179:1–29.PubMed
74.
Chen J, Wu W, Zhang M, Chen C. Taraxasterol suppresses inflammation in IL-1β-induced rheumatoid arthritis fibroblast-like synoviocytes and rheumatoid arthritis progression in mice. Int Immunopharmacol. 2019;70:274–83.PubMedCrossRef
75.
Yu WG, Shen Y, Wu JZ, Gao YB, Zhang LX. Madecassoside impedes invasion of rheumatoid fibroblast-like synoviocyte from adjuvant arthritis rats via inhibition of NF-κB-mediated matrix metalloproteinase-13 expression. Chin J Nat Med. 2018;16(5):330–8.PubMed
76.
Gao Q, Qin H, Zhu L, Li D, Hao X. Celastrol attenuates collagen-induced arthritis via inhibiting oxidative stress in rats. Int Immunopharmacol. 2020;84: 106527.PubMedCrossRef
77.
Li N, Gong Z, Li X, Ma Q, Wu M, Liu D, Deng L, Pan D, Liu Q, Wei Z, Wang Q, Han L, Lin C, Chen J. Betulinic acid inhibits the migration and invasion of fibroblast-like synoviocytes from patients with rheumatoid arthritis. Int Immunopharmacol. 2019;67:186–93.PubMedCrossRef
78.
Zhang C, Ma K, Yang Y, Wang F, Li W. Glaucocalyxin A suppresses inflammatory responses and induces apoptosis in TNF-a-induced human rheumatoid arthritis via modulation of the STAT3 pathway. Chem Biol Interact. 2021;341: 109451.PubMedCrossRef
79.
Li X, Yuan K, Zhu Q, Lu Q, Jiang H, Zhu M, Huang G, Xu A. Andrographolide ameliorates rheumatoid arthritis by regulating the apoptosis-NETosis balance of neutrophils. Int J Mol Sci. 2019;20:20.
80.
Yuan K, Li X, Lu Q, Zhu Q, Jiang H, Wang T, Huang G, Xu A. Application and Mechanisms of triptolide in the treatment of inflammatory diseases-a review. Front Pharmacol. 2019;10:1469.PubMedPubMedCentralCrossRef
81.
Aufschnaiter A, Kohler V, Khalifa S, Abd El-Wahed A, Du M, El-Seedi H, Büttner S. Apitoxin and its components against cancer, neurodegeneration and rheumatoid arthritis: Limitations and possibilities. Toxins. 2020;12(2):66.PubMedPubMedCentralCrossRef
82.
Mei L, Lin C, Lei S, Xu L, Fan YS. Small peptides compound isolated from agkistrodon with antiarthritic effect in collagen-induced arthritis rats. Evid Based Complement Alternat Med. 2018;2018:8265150.PubMedPubMedCentralCrossRef
83.
Meng M, Wang L, Yao Y, Lin D, Wang C, Yao J, Sun H, Liu M. Ganoderma lucidum polysaccharide peptide (GLPP) attenuates rheumatic arthritis in rats through inactivating NF-κB and MAPK signaling pathways. Phytomedicine. 2023;119: 155010.PubMedCrossRef
84.
Zhou Q, Li T, Fang G, Pang Y, Wang X. Bioactive molecules against rheumatoid arthritis by suppressing pyroptosis. Pharmaceuticals. 2023;16(7):952.PubMedPubMedCentralCrossRef
85.
Park YJ, Park B, Lee M, Jeong YS, Lee HY, Sohn DH, Song JJ, Lee JH, Hwang JS, Bae Y-S. A novel antimicrobial peptide acting via formyl peptide receptor 2 shows therapeutic effects against rheumatoid arthritis. Sci Rep. 2018;8(1):14664.PubMedPubMedCentralCrossRef
86.
Wang X, Li L, Wang J, Dong L, Shu Y, Liang Y, Shi L, Xu C, Zhou Y, Wang Y. Inhibition of cytokine response to TLR stimulation and alleviation of collagen-induced arthritis in mice by Schistosoma japonicum peptide SJMHE 1. J Cell Mol Med. 2017;21(3):475–86.PubMedCrossRef
87.
Chen Y, Shao S, Huang J, Gu Y, Cheng Y, Zhu X. Therapeutic efficacy of a Trichinella spiralis paramyosin-derived peptide modified with a membrane-targeting signal in mice with antigen-induced arthritis. Front Microbiol. 2020;11: 608380.PubMedPubMedCentralCrossRef
88.
Logashina YA, Palikova YA, Palikov VA, Kazakov VA, Smolskaya SV, Dyachenko IA, Tarasova NV, Andreev YA. Anti-inflammatory and analgesic effects of TRPV1 polypeptide modulator APHC3 in models of osteo-and rheumatoid arthritis. Mar Drugs. 2021;19(1):39.PubMedPubMedCentralCrossRef
89.
Ni LL, Che YH, Sun HM, et al. The therapeutic effect of wasp venom (Vespa magnifica, Smith) and its effective part on rheumatoid arthritis fibroblast-like synoviocytes through modulating inflammation, redox homeostasis and ferroptosis. J Ethnopharmacol. 2023;317:116700.PubMedCrossRef
90.
Zhang Z, Wan H, Han J, Sun X, Yu R, Liu B, Lu C, Zhou J, Su X. Ameliorative effect of tuna elastin peptides on AIA mice by regulating the composition of intestinal microorganisms and SCFAs. J Funct Foods. 2022;92.CrossRef
91.
Hussain T, Gupta S, Adhami VM, Mukhtar H. Green tea constituent epigallocatechin-3-gallate selectively inhibits COX-2 without affecting COX-1 expression in human prostate carcinoma cells. Int J Cancer. 2005;113(4):660–9.PubMedCrossRef
92.
Fujiki H, Suganuma M. Green tea: an effective synergist with anticancer drugs for tertiary cancer prevention. Cancer Lett. 2012;324(2):119–25.PubMedCrossRef
93.
Wood JN. From plant extract to molecular panacea: a commentary on Stone (1763) ‘An account of the success of the bark of the willow in the cure of the agues.’ Philos Trans R Soc Lond B Biol Sci. 2015;370:1666.CrossRef
94.
Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res. 2003;110(5–6):255–8.PubMedCrossRef
95.
Dhouibi R, Affes H, Ben Salem M, Hammami S, Sahnoun Z, Zeghal KM, Ksouda K. Screening of pharmacological uses of Urtica dioica and others benefits. Prog Biophys Mol Biol. 2020;150:67–77.PubMedCrossRef
96.
Bhusal KK, Magar SK, Thapa R, Lamsal A, Bhandari S, Maharjan R, Shrestha S, Shrestha J. Nutritional and pharmacological importance of stinging nettle (Urtica dioica L.): A review, Heliyon 2022;8(6):e09717.
97.
Lipsky PE, Tao XL. A potential new treatment for rheumatoid arthritis: thunder god vine. Semin Arthritis Rheum. 1997;26(5):713–23.PubMedCrossRef
98.
Tang Y, Liu Q, Feng Y, Zhang Y, Xu Z, Wen C, Zhang Y. Tripterygium ingredients for pathogenicity cells in rheumatoid arthritis. Front Pharmacol. 2020;11: 583171.PubMedPubMedCentralCrossRef
99.
Covas M-I, Nyyssönen K, Poulsen HE, Kaikkonen J. Zunft H-JF, Kiesewetter H, Gaddi A, de la Torre R, Mursu J, Bäumler H, The effect of polyphenols in olive oil on heart disease risk factors: a randomized trial. Ann Intern Med. 2006;145(5):333–41.PubMedCrossRef
100.
Radu AF, Bungau SG. Management of rheumatoid arthritis: an overview. Cells. 2021;10:11.CrossRef
Metadaten
Titel
Natural Products and Traditional Herbal Medicines as Managerial Therapies to Combat Rheumatoid Arthritis
verfasst von
Neha Ghosh
Shivam Pathak
Malsawmdawngkimi
Gautam Kumar
Azka Gull
Publikationsdatum
01.12.2024
Verlag
Springer US
Erschienen in
Clinical & Translational Metabolism / Ausgabe 1/2024
Print ISSN: 1534-8644
Elektronische ISSN: 2948-2445
DOI
https://doi.org/10.1007/s12018-024-09290-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise